- Home
- ALEC vs XERS Comparison
ALEC vs XERS Comparison
Compare ALEC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- XERS
- Stock Information
- Founded
- ALEC 2013
- XERS 2005
- Country
- ALEC United States
- XERS United States
- Employees
- ALEC N/A
- XERS N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- ALEC Health Care
- XERS Health Care
- Exchange
- ALEC Nasdaq
- XERS Nasdaq
- Market Cap
- ALEC 454.5M
- XERS 444.0M
- IPO Year
- ALEC 2019
- XERS 2018
- Fundamental
- Price
- ALEC $3.94
- XERS $3.09
- Analyst Decision
- ALEC Strong Buy
- XERS Buy
- Analyst Count
- ALEC 5
- XERS 3
- Target Price
- ALEC $20.67
- XERS $4.87
- AVG Volume (30 Days)
- ALEC 774.1K
- XERS 1.9M
- Earning Date
- ALEC 11-06-2024
- XERS 11-08-2024
- Dividend Yield
- ALEC N/A
- XERS N/A
- EPS Growth
- ALEC N/A
- XERS N/A
- EPS
- ALEC N/A
- XERS N/A
- Revenue
- ALEC $61,508,000.00
- XERS $187,361,000.00
- Revenue This Year
- ALEC N/A
- XERS $20.35
- Revenue Next Year
- ALEC $118.87
- XERS $16.14
- P/E Ratio
- ALEC N/A
- XERS N/A
- Revenue Growth
- ALEC N/A
- XERS 22.72
- 52 Week Low
- ALEC $3.49
- XERS $1.69
- 52 Week High
- ALEC $8.90
- XERS $3.64
- Technical
- Relative Strength Index (RSI)
- ALEC 38.47
- XERS 49.74
- Support Level
- ALEC $3.49
- XERS $2.82
- Resistance Level
- ALEC $6.14
- XERS $3.12
- Average True Range (ATR)
- ALEC 0.48
- XERS 0.18
- MACD
- ALEC -0.17
- XERS -0.03
- Stochastic Oscillator
- ALEC 16.98
- XERS 32.93
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.